Covered recipient · General Payments record
EDUARDO GUAJARDO GARZA
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2024
$4,085.42
- Reported across 195 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $417.05 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SHIELD THERAPEUTICS INC | $116.78 | 2 |
| ABBVIE INC. | $78.09 | 3 |
| Biogen, Inc. | $71.46 | 3 |
| MAYNE PHARMA COMMERCIAL LLC | $47.29 | 3 |
| Astellas Pharma US Inc | $29.73 | 1 |
| DAVOL INC. | $20.61 | 1 |
| PFIZER INC. | $20.46 | 1 |
| Aspira Women's Health Inc | $17.33 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $15.30 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.25 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103779235 | CMS |
| ABBVIE INC. | $22.03 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103779237 | CMS |
| ABBVIE INC. | $28.81 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103779239 | CMS |
| Aspira Women's Health Inc | $17.33 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126779818 | CMS |
| Astellas Pharma US Inc | $29.73 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139342192 | CMS |
| Biogen, Inc. | $20.16 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104873184 | CMS |
| Biogen, Inc. | $27.90 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104846902 | CMS |
| Biogen, Inc. | $23.40 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104838181 | CMS |
| Boston Scientific Corporation | $15.30 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092715022 | CMS |
| Davol Inc. | $20.61 | 01/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127659153 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $13.71 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154708771 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $15.44 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154708965 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $18.14 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154709175 | CMS |
| PFIZER INC. | $20.46 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131280938 | CMS |
| SHIELD THERAPEUTICS INC | $19.46 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150135467 | CMS |
| SHIELD THERAPEUTICS INC | $97.32 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150139005 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.